My Life, Our Future: Enrolling Through December 15, 2017 We strive toward enrolling 2,000 confirmed hemophilia carriers in the MLOF Research Repository.Read More Novel Technologies A Better Way to Treat Hepatitis Like hepatitis C, hepatitis B is a viral infection in the liver. The infection can be acute or chronic, in...Read More Novel Technologies New Test for VWD Promises Better Diagnostics The most common inherited bleeding disorder, von Willebrand disease (VWD) has also been one of the most difficult to diagnose...Read More Novel Technologies New Hemophilia Treatments: Subcutaneous Injection Two subcutaneous therapies are currently being investigated.Read More Novel Technologies The Power of Genetic Testing for Hemophilia MLOF is open to all people with hemophilia A and B.Read More Novel Technologies Hemophilia Gene Therapy Comes of Age More than 100 researchers met for NHF's 13th Workshop on Novel Technologies and Gene Transfer for Hemophilia.Read More Novel Technologies Unlocking Hemophilia The MLOF Research Repository will allow researchers to explore long-unanswered questions about hemophilia.Read More Novel Technologies Six at a Time Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6.Read More Novel Technologies FVII Gene Therapy Trial in Dogs; New FIX and HCV Drugs An update on FVII gene therapy and more.Read More Novel Technologies FDA in Action Updates on Daklinza, Technivie, and the ACE910 trialRead More Novel Technologies Progress Made for My Life, Our Future Genotyping Initiative Five pilot sites have been approved and first patients enrolledRead More Novel Technologies Workshop Examines Emerging Hemophilia Therapies A workshop on new bleeding disorders therapies provided insights on improved clotting factors, immune responses to new treatments and gene...Read More Novel Technologies
